Telomir Pharms Stock Price, News & Analysis

Telomir Pharmaceuticals (NASDAQ:TELO) reported preclinical results dated October 7, 2025 showing its candidate Telomir-1 reset DNA methylation and reactivated tumor suppressor genes MASPIN and RASSF1A in aggressive prostate cancer models.

Key findings: dose-dependent reduction in RASSF1A methylation, reversal of chemotherapy-induced MASPIN hypermethylation, ~50% tumor volume reduction in vivo, and elimination of chemotherapy-related mortality in the reported models. Telomir-1 also showed prior preclinical effects on STAT1, CDKN2A, histone demethylases, mitochondrial function, and telomere/epigenetic markers. Telomir is advancing Telomir-1 into IND-enabling preclinical studies.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced significant new in vitro data for its lead compound Telomir-1, revealing its ability to inhibit KDM5 family members, adding to its previously known KDM2/KDM6 and DNA methylation activity.

The breakthrough demonstrates Telomir-1's potential as a first-in-class broad-spectrum epigenetic reset therapy. The compound targets both histone demethylases and DNA methylation, key mechanisms in cancer progression and aging. In previous studies, Telomir-1 showed greater activity than chemotherapy and rapamycin in reducing abnormal DNA methylation and reactivating tumor suppressors.

The company is currently advancing IND-enabling studies and GMP scale-up for Telomir-1, with ongoing preclinical evaluations in aggressive cancers and aging models.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced significant preclinical data showing that its drug candidate Telomir-1 effectively resets DNA methylation to reactivate CDKN2A, a crucial tumor suppressor gene, in aggressive prostate cancer cells. The study demonstrated that Telomir-1 outperformed both Rapamycin and chemotherapy in inhibiting CDKN2A DNA methylation.

The findings build upon previous research showing Telomir-1's ability to reset STAT1, suggesting the drug can broadly reverse cancer-induced silencing of key tumor suppressors through two mechanisms: controlling unchecked cell growth and preventing immune evasion. The company is advancing its pre-IND program with ongoing CMC activities and IND-enabling studies, positioning Telomir-1 as a potential first-in-class longevity drug candidate targeting both cancer and aging.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced new in vitro data for its lead drug candidate, Telomir-1, revealing its potential as a first-in-class epigenetic therapy. The drug demonstrates potent inhibition of UTX (KDM6A), an enzyme crucial for DNA methylation and gene regulation.

The studies, conducted by Eurofins Discovery, show that Telomir-1 can effectively block multiple epigenetic enzymes including FBXL10, FBXL11, and JMJD3, while maintaining selectivity by not affecting GCN5L2. The drug also exhibits low-level inhibitory activity against Tankyrases, potentially disrupting cancer growth pathways without causing telomere-related toxicity.

This breakthrough suggests Telomir-1's potential applications in treating cancer, autoimmune disorders, neurodegeneration, autism spectrum disorder, metabolic dysfunction, and age-related diseases by resetting faulty DNA methylation patterns and restoring proper gene control.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced groundbreaking preclinical data showing that its lead compound Telomir-1 effectively inhibits three key histone demethylase enzymes: JMJD3, FBXL10, and FBXL11. These enzymes are crucial regulators of gene expression and are implicated in various diseases.

The study, conducted with Eurofins Discovery, demonstrates Telomir-1's potential to treat multiple conditions through epigenetic modulation, including cancer, autoimmune disorders, neurodegeneration, and metabolic dysfunction. The compound has shown superior performance compared to Paclitaxel and Rapamycin in preclinical cancer models, particularly in reactivating tumor suppressor genes.

The company is advancing Telomir-1's development and plans to finalize its first IND-enabling program, marking a significant step toward clinical trials.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced promising preclinical results for its lead compound Telomir-1 in treating mitochondrial dysfunction. The study, conducted with Smart Assays Biotechnologies, demonstrated that Telomir-1 successfully restored mitochondrial function in Hutchinson-Gilford Progeria Syndrome (HGPS) cells without triggering oxidative stress or cell proliferation.

Key findings show that Telomir-1 increased mitochondrial energy production, reduced reactive oxygen species (ROS), and showed stronger effects in diseased cells compared to healthy controls. The compound's unique profile suggests potential applications in treating neurodegenerative conditions including Parkinson's, Alzheimer's, and ALS, where mitochondrial failure drives disease progression.

The company is currently finalizing IND-enabling work and evaluating potential clinical indications for Telomir-1's development pathway.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced breakthrough preclinical findings for its Telomir-1 drug candidate in treating aggressive prostate cancer. The study demonstrated that Telomir-1 successfully reversed epigenetic gene silencing of STAT1, a crucial tumor suppressor, outperforming both Paclitaxel and Rapamycin in PC3 xenograft models.

The drug showed superior efficacy in a 21-day oral administration trial, fully reversing STAT1 hypermethylation in a dose-dependent manner. Additionally, Telomir-1 reduced hypermethylation of TMS1, another key tumor suppressor, while maintaining a favorable safety profile by not elongating telomeres in cancerous cells.

These findings build upon previous March 2025 results where Telomir-1 reduced tumor volume by approximately 50% and eliminated chemotherapy-induced mortality when combined with Paclitaxel.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced promising preclinical data showing its lead candidate, Telomir-1, successfully prevented cellular aging in human progeria cell lines. The study, conducted by Smart Assays using cells from the Progeria Research Foundation, demonstrated significant improvements in cell viability, reduction of oxidative stress, and restoration of mitochondrial function. Progeria (HGPS) is an ultra-rare genetic disorder affecting 400-500 people worldwide, causing rapid aging in children with an average life expectancy of 13-15 years. The current FDA-approved treatment, Zokinvy, only extends lifespan by 4.3 years without addressing underlying disease mechanisms. Telomir-1 showed effectiveness in regulating intracellular metal ions, reducing oxidative stress, restoring mitochondrial function, and addressing other critical aging pathways. The company is finalizing IND-enabling studies and plans to engage with the FDA for potential orphan drug designation.

Telomir Pharmaceuticals (NASDAQ:TELO) announced breakthrough preclinical results for Telomir-1 in treating Wilson's disease, a rare genetic disorder causing copper accumulation. In ATP7B C271X -/- zebrafish models, the drug demonstrated significant dose-dependent improvements including 4-5x reduction in tremors, 50% reduction in liver copper accumulation, and normalization of critical liver biomarkers (ALT, AST, bilirubin). The treatment reversed neurological symptoms, liver and kidney damage, while improving survival rates. These results build upon previous successful studies in Werner syndrome and Age-Related Macular Degeneration, highlighting Telomir-1's broad therapeutic potential. The company plans to file its first IND by end of 2025, with human clinical trials scheduled for early 2026.